 |
|
|
Important Notice: The Forum does not endorse any medical
product or therapy. ALL medications and supplements
should be taken ONLY under the supervision of a physician,
due to the possibility of side-effects, drug interactions,
etc.
|
Animal Model:
|
HB-EGF Forebrain-Specific KO Mice
|
|
Preparation Type:
|
Genetic Preparations
|
|
DA-related behavior:
|
Hyperactive in novel setting and home cage
|
|
Gating:
|
PPI deficits
|
|
Cognitive behavior:
|
Impaired novel object recognition
|
|
Social behavior:
|
Decreased social interaction
|
|
Molecular/morphological signature:
|
Reduced dopamine, serotonin, PSD-95 and NR1 in prefrontal cortex
|
|
Response to APD:
|
Hyperactivity reduced by haloperidol and clozapine; PPI
deficits reduced by risperidone and clozapine; clozapine but
not haloperidol improved social behavior
|
|
|
|
|
|
Text Size 
See our most recent Schizophrenia Bulletin theme Webinar: